Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Blood (2025) 146 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2025-4232

Published: 2025

Journal Articles

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Blood (2025) 146 (Supplement 1): 936.

https://doi.org/10.1182/blood-2025-936

Published: 2025

Journal Articles

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Blood (2025) 146 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2025-4198

Published: 2025

Journal Articles

Cytotoxic, natural killer-like ex-tissue resident memory T-cells circulate in human chronic graft-versus-host disease at diagnosis

Patrick Mellors, Olga Shestova, Linda Perry, Nasheed Hossain, Noelle Frey, Mary Ellen Martin, Pashna Munshi, Alison Loren, Elizabeth Hexner, David Porter, Saar Gill

Blood (2025) 146 (Supplement 1): 821.

https://doi.org/10.1182/blood-2025-821

Published: 2025

Journal Articles

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Blood (2025) 146 (Supplement 1): 818.

https://doi.org/10.1182/blood-2025-818

Published: 2025

Journal Articles

IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 812.

https://doi.org/10.1182/blood-2025-812

Published: 2025

Journal Articles

Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study

Blood (2025) 146 (Supplement 1): 7189.

https://doi.org/10.1182/blood-2025-7189

Published: 2025

Journal Articles

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

John Koreth, Maria Carmen Martinez Munoz, Jeremy Pantin, Shukaib Arslan, Jaime Sanz, Alison Loren, Benedetta Rambaldi, Elisa Sala, Avichai Shimoni, Tsila Zuckerman, Corey Cutler, Lisette Acevedo, Kham Phenis, Eugene Sun, Stephen Connelly, Joel Rothman

Blood (2025) 146 (Supplement 1): 274.

https://doi.org/10.1182/blood-2025-274

Published: 2025

Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Blood (2023) 142 (Supplement 1): 475.

https://doi.org/10.1182/blood-2023-188032

Published: 2023

Journal Articles

Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Clinton Yam, MBBS, Daniel J. Landsburg, MD, Xinyi Lin, PhD, Anthony Mato, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Noelle Frey, MD, Edward A. Stadtmauer, MD, David Porter, MD, Stephen J. Schuster, MD, Sunita Dwivedy Nasta, MD

Blood (2015) 126 (23): 3183.

https://doi.org/10.1182/blood.V126.23.3183.3183

Published: 2015

Journal Articles

Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation

Clinton Yam, MBBS, Lisa Crisalli, BS, Selina Luger, MD, Alison Loren, MD MS, Elizabeth O Hexner, MD, Noelle Frey, MD, James Mangan, MD PhD, Amy Gao, MS, Edward A. Stadtmauer, MD, David Porter, MD, Ran Reshef, MD

Blood (2015) 126 (23): 4380.

https://doi.org/10.1182/blood.V126.23.4380.4380

Published: 2015

Journal Articles

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Jie Wang, MD, Jennifer J.D. Morrissette, PhD, E. Paul Wileyto, PhD, Stephen J. Schuster, MD, Alexandra Vandegrift, BA, Allison Rago, BSN, Colleen Dorsey, BSN, David Porter, MD, Daniel J. Landsburg, MD, Prioty Islam, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Scott Weber, BS, Edward A. Stadtmauer, MD, Anthony Mato, MD

Blood (2015) 126 (23): 2929.

https://doi.org/10.1182/blood.V126.23.2929.2929

Published: 2015

Journal Articles

Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

Jonathan Canaani, MD, Marlise R. Luskin, MD, Alison Loren, MD MS, Colleen Timlin, PharmD, BCOP, James Mangan, MD PhD, Elizabeth O. Hexner, MD, Noelle V. Frey, MDMS, David L Porter, MD, Edward A. Stadtmauer, MD, Selina Luger, MD

Blood (2015) 126 (23): 2543.

https://doi.org/10.1182/blood.V126.23.2543.2543

Published: 2015

Journal Articles

A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML

Marlise R. Luskin, MD, Phyllis Gimotty, PhD, Catherine Smith, Alison Loren, MD MS, Maria Figueroa, MD, Jenna Harrison, Zhuoxin Sun, PhD, Martin S Tallman, MD, Elisabeth Paietta, PhD, Mark R Litzow, MD, Ross L. Levine, MD, Hugo F. Fernandez, MD, Selina Luger, MD, Martin Carroll, MD, Stephen Master, MD PhD, Gerald Wertheim, MD PhD

Blood (2015) 126 (23): 2591.

https://doi.org/10.1182/blood.V126.23.2591.2591

Published: 2015

Journal Articles

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

Marc Hoffmann, MD, Tahamtan Ahmadi, MD, PhD, Erin Cobain, MD, Alison Loren, Noelle V Frey, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Sunita D. Nasta, MD

Blood (2011) 118 (21): 4950.

https://doi.org/10.1182/blood.V118.21.4950.4950

Published: 2011

Journal Articles

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Steven C Goldstein, MD, Selina M. Luger, MD, Noelle Frey, MD, Alexander Perl, MD, Edward A Stadtmauer, MD, Donald Tsai, MD, Alison Loren, MD, Sunita Nasta, MD, Elizabeth Hexner, MD, Ran Reshef, MD, Jacqueline Smith, CRNP, Joanne Hinkle, Pavel Vassilev, BS, Michael J Vozniak, PharmD, David L. Porter, MD

Blood (2010) 116 (21): 4519.

https://doi.org/10.1182/blood.V116.21.4519.4519

Published: 2010

Journal Articles

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Vikram R Paralkar, MD, Sunita Dwivedy Nasta, MD, Kelly Morrissey, MD, Jacqueline Smith, MSN, CRNP, Pavel Vassilev, BS, Mary Ellen Martin, MD, Steven C Goldstein, MD, Alison Loren, MD, MPH, Alain H Rook, MD, Ellen J Kim, MD, David L Porter, MD

Blood (2010) 116 (21): 4574.

https://doi.org/10.1182/blood.V116.21.4574.4574

Published: 2010

Journal Articles

A Comparison of Two Induction Regimens for Older Patients with Acute Lymphoblastic Leukemia: Daunorubicin, Vincristine and Prednisone (DVP) is Worth Considering

Daniel Landsburg, David Porter, Edward Stadtmauer, Alison Loren, Donald Tsai, Noelle Frey, Steven Goldstein, Elizabeth Hexner, Sunita Dwivedy Nasta, Alexander Perl, Jennifer Davis, Selina Luger

Blood (2010) 116 (21): 3252.

https://doi.org/10.1182/blood.V116.21.3252.3252

Published: 2010

Journal Articles

Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease

Courtney D. DiNardo, MD, Alison Loren, MD, Steven Goldstein, MD, Stephen J. Schuster, Alexander Perl, MD, Donald Tsai, MD, Noelle Frey, MD, Elizabeth Hexner, MD, Ran Reshef, MD, Edward A. Stadtmauer, MD, David L. Porter, MD, Selina Luger, MD

Blood (2010) 116 (21): 2366.

https://doi.org/10.1182/blood.V116.21.2366.2366

Published: 2010

Journal Articles

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Steven C Goldstein, MD, Bruce Levine, PhD, Jacqueline Smith, MSN, CRNP, Joanne Hinkle, RN, BSN, OCN, Selina Luger, MD, Alexander Perl, MD, Alison Loren, MD, Noelle Frey, MD, Edward Stadtmauer, MD, Daniel Schullery, PhD, Jean Boyer, PhD, Dennis L. Confer, MD, David Porter, MD, Carl H. June, MD

Blood (2008) 112 (11): 468.

https://doi.org/10.1182/blood.V112.11.468.468

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Cytotoxic, natural killer-like ex-tissue resident memory T-cells circulate in human chronic graft-versus-host disease at diagnosis

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia

Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

A Comparison of Two Induction Regimens for Older Patients with Acute Lymphoblastic Leukemia: Daunorubicin, Vincristine and Prednisone (DVP) is Worth Considering

Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only